Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | CES1 | P23141 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | APAF1 | O14727 | 2/20 | 0.36 |
| ▸ | TDP2 | O95551 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451688 | 0.76 | MAOA (0.46) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL1450361 | 0.76 | MEN1 (0.38) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL855431 | 0.68 | MAOA (0.56) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL88188 | 0.68 | CES1 (0.52) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL29385474 | 0.68 | MAOA (0.56) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL29353628 | 0.68 | CES1 (0.52) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL2095985 | 0.68 | KMT2A (0.50) | S100A4MEN1KMT2ACDC25BMAOA | |
| SCHEMBL224107 | 0.67 | MAOB (0.42) | MEN1KMT2ACDC25BMAOACES1 | |
| SCHEMBL31741221 | 0.66 | CES1 (0.50) | S100A4MEN1KMT2ACDC25BMAOA | |
| Water SCHEMBL460840 | 0.66 | MAOA (0.54) | S100A4MEN1KMT2ACDC25BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820985-B1 | Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-08-30 | — | — | EP | claimed |
| US-5854273-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 1998-12-29 | — | — | US | claimed |
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-11-27 | — | — | US | disclosed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177187-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-6300340-B1 | USEFUL FOR THERAPY OF CANCER AND SOLID TUMORS | ADIR ET COMPAGNIE (FR) | 2001-10-09 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| US-6162822-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 2000-12-19 | — | — | US | disclosed |
| WO-2000064888-A1 | DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| US-5854273-A | Bisimide compounds | ADIR ET COMPAGNIE (FR) | 1998-12-29 | — | — | US | disclosed |
| EP-0820985-A1 | Bis imide derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-01-28 | — | — | EP | disclosed |
| EP-0163609-A2 | Process for dyeing a high molecular organic material, polycyclic compounds and their preparation | CIBA-GEIGY AG (CH) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | PPARG, PPARA, PPARD | S100A4 2622/4885MEN1 4879/4885KMT2A 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.